Patents by Inventor Lawrence D. Papsidero

Lawrence D. Papsidero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6723518
    Abstract: An isolated chemokine is disclosed. The isolated chemokine is expressed preferentially in breast tissue or can be detected in breast milk. It includes from about 100 to about 132 amino acids, has a deduced molecular weight of from about 10 to about 16 kDa, and has a deduced isoionic point of from about pH 10.1 to about pH 10.7. Antibodies and binding portions thereof recognizing the subject chemokine and peptides which include the antigenic portions of the subject chemokines are described. DNA molecules which encode the subject chemokines as well as nucleic acid molecules which, under stringent conditions, hybridize to nucleic acid molecules encoding the subject chemokines or to a complement thereof are also disclosed.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: April 20, 2004
    Assignee: Codon Diagnostics, LLC
    Inventors: Lawrence D. Papsidero, Lyn M. Dyster, Jana M. Frustaci
  • Publication number: 20030026777
    Abstract: An isolated chemokine is disclosed. The isolated chemokine is expressed preferentially in breast tissue or can be detected in breast milk. It includes from about 100 to about 132 amino acids, has a deduced molecular weight of from about 10 to about 16 kDa, and has a deduced isoionic point of from about pH 10.1 to about pH 10.7. Antibodies and binding portions thereof recognizing the subject chemokine and peptides which include the antigenic portions of the subject chemokines are described. DNA molecules which encode the subject chemokines as well as nucleic acid molecules which, under stringent conditions, hybridize to nucleic acid molecules encoding the subject chemokines or to a complement thereof are also disclosed.
    Type: Application
    Filed: April 13, 2001
    Publication date: February 6, 2003
    Applicant: Codon Diagnostics, LLC
    Inventors: Lawrence D. Papsidero, Lyn M. Dyster, Jana M. Frustaci
  • Publication number: 20020076710
    Abstract: An isolated chemokine is disclosed. The isolated chemokine is expressed preferentially in breast tissue or can be detected in breast milk. It includes from about 100 to about 132 amino acids, has a deduced molecular weight of from about 10 to about 16 kDa, and has a deduced isoionic point of from about pH 10.1 to about pH 10.7. Antibodies and binding portions thereof recognizing the subject chemokine and peptides which include the antigenic portions of the subject chemokines are described. DNA molecules which encode the subject chemokines as well as nucleic acid molecules which, under stringent conditions, hybridize to nucleic acid molecules encoding the subject chemokines or to a complement thereof are also disclosed.
    Type: Application
    Filed: April 13, 2001
    Publication date: June 20, 2002
    Applicant: Codon Diagnostics, LLC
    Inventors: Lawrence D. Papsidero, Lyn M. Dyster, Jana M. Frustaci
  • Patent number: 6306653
    Abstract: An isolated chemokine is disclosed. The isolated chemokine is expressed preferentially in breast tissue or can be detected in breast milk. It includes from about 100 to about 132 amino acids, has a deduced molecular weight of from about 10 to about 16 kDa, and has a deduced isoionic point of from about pH 10.1 to about pH 10.7. Antibodies and binding portions thereof recognizing the subject chemokine and peptides which include the antigenic portions of the subject chemokines are described. DNA molecules which encode the subject chemokines as well as nucleic acid molecules which, under stringent conditions, hybridize to nucleic acid molecules encoding the subject chemokines or to a complement thereof are also disclosed.
    Type: Grant
    Filed: September 3, 1998
    Date of Patent: October 23, 2001
    Assignee: Codon Diagnostics, LLC
    Inventors: Lawrence D. Papsidero, Lyn M. Dyster, Jana M. Frustaci
  • Patent number: 5871936
    Abstract: Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: February 16, 1999
    Assignee: Health Research, Inc.
    Inventors: Tsann Ming Chu, Lawrence D. Papsidero
  • Patent number: 5798445
    Abstract: Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.
    Type: Grant
    Filed: October 17, 1996
    Date of Patent: August 25, 1998
    Assignee: Health Research, Inc.
    Inventors: Tsann Ming Chu, Lawrence D. Papsidero
  • Patent number: 5652114
    Abstract: Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid human breast tumors xenografted in nude mice. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.
    Type: Grant
    Filed: September 18, 1989
    Date of Patent: July 29, 1997
    Assignee: Health Research Inc.
    Inventors: Tsann Ming Chu, Lawrence D. Papsidero, Gary A. Croghan
  • Patent number: 5185147
    Abstract: Polypeptides in the size range 6-11 amino acids from discrete regions of the human immunodeficiency virus p17 protein are immunogenic and form the basis for diagnosis and therapy of HIV-related disease.
    Type: Grant
    Filed: August 19, 1988
    Date of Patent: February 9, 1993
    Assignee: Cellular Products, Inc.
    Inventor: Lawrence D. Papsidero
  • Patent number: 5039604
    Abstract: A kit and method have been developed which can be used to simultaneously detect antibodies to two HTLV or HIV antigens. The kit includes a solid carrier material, such as a microtest plate, having immobilized thereon a mixture of first and second viral antigens. The antigens are from any of HTLV-I, HTLV-II, HIV-I and HIV-II provided, however, that HTLV-II antigen is mixed only with HTLV-I antigen. The kit also comprises labeled-antibodies which are reactive with both the first and second antibodies in a test sample. A biological sample, such as a blood sample, is assayed by contacting it with the immobilized antigens to form reaction products between the immobilized antigens and the antibodies in the sample, followed by contact with the labeled antibodies to form labeled reaction products which can be detected in a suitable manner. The kit and method are useful for rapid screening of biological fluids.
    Type: Grant
    Filed: August 21, 1987
    Date of Patent: August 13, 1991
    Assignee: Cellular Products, Inc.
    Inventor: Lawrence D. Papsidero
  • Patent number: 4939240
    Abstract: Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.
    Type: Grant
    Filed: September 11, 1985
    Date of Patent: July 3, 1990
    Assignee: Health Research, Inc.
    Inventors: Tsann M. Chu, Lawrence D. Papsidero